You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昊海生物科技(06826.HK)年度淨利潤減少37.95%至2.3億元 末期息0.5元
格隆匯 03-27 00:01

格隆匯3月26日丨昊海生物科技(06826.HK)公佈,截至2020年12月31日止年度,公司實現營業收入約為人民幣13.24億元,降幅約為16.99%;歸屬於上市公司股東的淨利潤及歸屬於上市公司股東的扣除非經常性損益的淨利潤分別約為人民幣2.3億元和人民幣2.06億元,較2019年度分別下降約37.95%和42.25%。董事會建議派發年度末期股息為每股人民幣0.50元(含税)。

淨利潤減少主要系報吿期內上半年營業收入受疫情影響較大所致,至2020年下半年,集團歸屬於上市公司股東的淨利潤已恢復同比增長。

報吿期內,集團持續加大研發投入,着重擴充眼科和醫美創新型產品的研發管路,報吿期內研發費用由上年度的約人民幣1.16億元上升至約人民幣1.26億元,增幅約為8.95%,研發費用佔營業收入比重由上年度的7.28%增長到9.55%。

2021年,集團將繼續發揮管理團隊在整合戰略性資產方面擁有的卓越往績、資源優勢及豐富經驗,在研發、生產、銷售和服務等各個環節進一步加強對已併購企業的整合,以最大化發揮協同作用、提升運營效率、發展創新技術、拓展市場空間為目的,使併購企業能迅速融入集團管理體系,持續提升整體核心競爭力。

在研發方面,集團將聯動位於中國、美國、英國、以色列的優勢研發資源,加大創新型產品的研發投入,持續推進產品組合的優化升級,擴展產品臨牀應用,確保眼科、醫美、骨科、外科四大治療領域的技術領先優勢。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account